Cargando…

The Survival Effect of Chest Wall With or Without Regional Lymphatic Radiotherapy for Breast Cancer Patients With T3~4N0M0

BACKGROUND: Peripheral lymphatic radiotherapy in patients with pT3N0M0 and pT4N0M0 breast cancer has been a matter of considerable debate among radiation oncologists. This is the first report in a non-Caucasian population. PATIENTS AND METHODS: The study included 165 pT3N0M0 and pT4N0M0 patients. Un...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Guanqiao, Yao, Jia, Chen, Junni, Cai, Baizhen, Lin, Xiangying, Chen, Zetan, Chen, Jiawei, Wang, Han, Yang, Shiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311914/
https://www.ncbi.nlm.nih.gov/pubmed/34322377
http://dx.doi.org/10.3389/fonc.2021.653831
_version_ 1783729052113174528
author Li, Guanqiao
Yao, Jia
Chen, Junni
Cai, Baizhen
Lin, Xiangying
Chen, Zetan
Chen, Jiawei
Wang, Han
Yang, Shiping
author_facet Li, Guanqiao
Yao, Jia
Chen, Junni
Cai, Baizhen
Lin, Xiangying
Chen, Zetan
Chen, Jiawei
Wang, Han
Yang, Shiping
author_sort Li, Guanqiao
collection PubMed
description BACKGROUND: Peripheral lymphatic radiotherapy in patients with pT3N0M0 and pT4N0M0 breast cancer has been a matter of considerable debate among radiation oncologists. This is the first report in a non-Caucasian population. PATIENTS AND METHODS: The study included 165 pT3N0M0 and pT4N0M0 patients. Univariate, multivariate, propensity score matching (PSM), and Kaplan-Meier analyses were conducted to evaluate the survival of patients. We also review all the literature about regional lymph nodes radiation in T3-4N0M0 patients and summarize them with tables to compare with the present study. RESULTS: The median follow-up duration was 58.7 months. Multivariate analyses showed that advance T stage and grade were dependent poor prognostic factors for OS, DMFS, LRFS, and DFS between group A (chest wall radiation) and group B (chest wall and regional lymph nodes radiation). The overall survival (OS), disease-free survival (DFS), local relapse-free survival (LRFS), and distant metastasis-free survival (DMFS) rates were not significantly different between group A and group B. The 5-year OS rate was 92.3% vs 89.7% for group A and group B, respectively (P=0.819). The 5-year LRFS rate was 94.9% vs 94.3% for group A and group B, respectively (P=0.852). Fifty-four pairs of patients were selected after propensity score matching (PSM) analysis was conducted. There was also no significant difference between group A and group B in regard to the OS, DFS, LRFS, and DMFS rates after PSM. The patients included in previous studies were all Caucasians, and our study was focused on non-Caucasians. The cases of previous studies were 10 to 20 years ago, but our study has more recent cases. The radiotherapy techniques of previous studies were conventional, and the techniques used in our study were three-dimensional conformal radiotherapy (3DCRT) or intensity modulated radiotherapy (IMRT). CONCLUSION: Both our study and previous studies suggested that regional lymph nodes radiation cannot improve the survival rate for breast cancer patients with T3-4N0M0 in non-Caucasian population. Advance T stage and grade were the dependent poor prognostic factors for T3-4N0M0 patients.
format Online
Article
Text
id pubmed-8311914
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83119142021-07-27 The Survival Effect of Chest Wall With or Without Regional Lymphatic Radiotherapy for Breast Cancer Patients With T3~4N0M0 Li, Guanqiao Yao, Jia Chen, Junni Cai, Baizhen Lin, Xiangying Chen, Zetan Chen, Jiawei Wang, Han Yang, Shiping Front Oncol Oncology BACKGROUND: Peripheral lymphatic radiotherapy in patients with pT3N0M0 and pT4N0M0 breast cancer has been a matter of considerable debate among radiation oncologists. This is the first report in a non-Caucasian population. PATIENTS AND METHODS: The study included 165 pT3N0M0 and pT4N0M0 patients. Univariate, multivariate, propensity score matching (PSM), and Kaplan-Meier analyses were conducted to evaluate the survival of patients. We also review all the literature about regional lymph nodes radiation in T3-4N0M0 patients and summarize them with tables to compare with the present study. RESULTS: The median follow-up duration was 58.7 months. Multivariate analyses showed that advance T stage and grade were dependent poor prognostic factors for OS, DMFS, LRFS, and DFS between group A (chest wall radiation) and group B (chest wall and regional lymph nodes radiation). The overall survival (OS), disease-free survival (DFS), local relapse-free survival (LRFS), and distant metastasis-free survival (DMFS) rates were not significantly different between group A and group B. The 5-year OS rate was 92.3% vs 89.7% for group A and group B, respectively (P=0.819). The 5-year LRFS rate was 94.9% vs 94.3% for group A and group B, respectively (P=0.852). Fifty-four pairs of patients were selected after propensity score matching (PSM) analysis was conducted. There was also no significant difference between group A and group B in regard to the OS, DFS, LRFS, and DMFS rates after PSM. The patients included in previous studies were all Caucasians, and our study was focused on non-Caucasians. The cases of previous studies were 10 to 20 years ago, but our study has more recent cases. The radiotherapy techniques of previous studies were conventional, and the techniques used in our study were three-dimensional conformal radiotherapy (3DCRT) or intensity modulated radiotherapy (IMRT). CONCLUSION: Both our study and previous studies suggested that regional lymph nodes radiation cannot improve the survival rate for breast cancer patients with T3-4N0M0 in non-Caucasian population. Advance T stage and grade were the dependent poor prognostic factors for T3-4N0M0 patients. Frontiers Media S.A. 2021-07-12 /pmc/articles/PMC8311914/ /pubmed/34322377 http://dx.doi.org/10.3389/fonc.2021.653831 Text en Copyright © 2021 Li, Yao, Chen, Cai, Lin, Chen, Chen, Wang and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Guanqiao
Yao, Jia
Chen, Junni
Cai, Baizhen
Lin, Xiangying
Chen, Zetan
Chen, Jiawei
Wang, Han
Yang, Shiping
The Survival Effect of Chest Wall With or Without Regional Lymphatic Radiotherapy for Breast Cancer Patients With T3~4N0M0
title The Survival Effect of Chest Wall With or Without Regional Lymphatic Radiotherapy for Breast Cancer Patients With T3~4N0M0
title_full The Survival Effect of Chest Wall With or Without Regional Lymphatic Radiotherapy for Breast Cancer Patients With T3~4N0M0
title_fullStr The Survival Effect of Chest Wall With or Without Regional Lymphatic Radiotherapy for Breast Cancer Patients With T3~4N0M0
title_full_unstemmed The Survival Effect of Chest Wall With or Without Regional Lymphatic Radiotherapy for Breast Cancer Patients With T3~4N0M0
title_short The Survival Effect of Chest Wall With or Without Regional Lymphatic Radiotherapy for Breast Cancer Patients With T3~4N0M0
title_sort survival effect of chest wall with or without regional lymphatic radiotherapy for breast cancer patients with t3~4n0m0
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311914/
https://www.ncbi.nlm.nih.gov/pubmed/34322377
http://dx.doi.org/10.3389/fonc.2021.653831
work_keys_str_mv AT liguanqiao thesurvivaleffectofchestwallwithorwithoutregionallymphaticradiotherapyforbreastcancerpatientswitht34n0m0
AT yaojia thesurvivaleffectofchestwallwithorwithoutregionallymphaticradiotherapyforbreastcancerpatientswitht34n0m0
AT chenjunni thesurvivaleffectofchestwallwithorwithoutregionallymphaticradiotherapyforbreastcancerpatientswitht34n0m0
AT caibaizhen thesurvivaleffectofchestwallwithorwithoutregionallymphaticradiotherapyforbreastcancerpatientswitht34n0m0
AT linxiangying thesurvivaleffectofchestwallwithorwithoutregionallymphaticradiotherapyforbreastcancerpatientswitht34n0m0
AT chenzetan thesurvivaleffectofchestwallwithorwithoutregionallymphaticradiotherapyforbreastcancerpatientswitht34n0m0
AT chenjiawei thesurvivaleffectofchestwallwithorwithoutregionallymphaticradiotherapyforbreastcancerpatientswitht34n0m0
AT wanghan thesurvivaleffectofchestwallwithorwithoutregionallymphaticradiotherapyforbreastcancerpatientswitht34n0m0
AT yangshiping thesurvivaleffectofchestwallwithorwithoutregionallymphaticradiotherapyforbreastcancerpatientswitht34n0m0
AT liguanqiao survivaleffectofchestwallwithorwithoutregionallymphaticradiotherapyforbreastcancerpatientswitht34n0m0
AT yaojia survivaleffectofchestwallwithorwithoutregionallymphaticradiotherapyforbreastcancerpatientswitht34n0m0
AT chenjunni survivaleffectofchestwallwithorwithoutregionallymphaticradiotherapyforbreastcancerpatientswitht34n0m0
AT caibaizhen survivaleffectofchestwallwithorwithoutregionallymphaticradiotherapyforbreastcancerpatientswitht34n0m0
AT linxiangying survivaleffectofchestwallwithorwithoutregionallymphaticradiotherapyforbreastcancerpatientswitht34n0m0
AT chenzetan survivaleffectofchestwallwithorwithoutregionallymphaticradiotherapyforbreastcancerpatientswitht34n0m0
AT chenjiawei survivaleffectofchestwallwithorwithoutregionallymphaticradiotherapyforbreastcancerpatientswitht34n0m0
AT wanghan survivaleffectofchestwallwithorwithoutregionallymphaticradiotherapyforbreastcancerpatientswitht34n0m0
AT yangshiping survivaleffectofchestwallwithorwithoutregionallymphaticradiotherapyforbreastcancerpatientswitht34n0m0